Successful In-vivo Results Peptide Vaccine T-Cell Expansion
Filed with ASX · · 3 pages · English
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- CEO Update
- March 2018 Operational Update and Cashflow
- Changes to Board and Management
- Cre Enzyme Delivery Provides Validation & Strategic Value
- Dec 2017 Half-year financial statements & Appendix 4D
Later from PYC Therapeutics
- Achievement of Major Milestone - In vivo Cre Delivery
- June 2018 Quarterly Operational Update and App4C
- Update on Capital Raising
- Suspension from Official Quotation
- Phylogica Recapitalisation
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics